Triple-negative breast cancer (TNBC), which constitutes approximately 12–17% of breast cancer cases, is a heterogeneous subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (2). Here, ERBB2 is linked to triple-negative breast carcinoma.